Literature DB >> 9820631

Intestinal permeability in patients with acute myeloid leukemia.

G M Sundström1, A Wahlin, I Nordin-Andersson, O B Suhr.   

Abstract

Intestinal permeability was studied in patients with acute myeloid leukemia (AML) before, during and after chemotherapy. Intestinal permeability was determined by the lactulose (La)/mannitol (Ma) absorption test in 16 adult patients with de novo AML. The hydrogen breath test was used to disclose bacterial fermentation of the test substances in the small intestine. The permeability was found significantly increased (p<0.02) in the patients before induction chemotherapy treatment. During induction treatment and throughout the cytopenic period the intestinal permeability was constantly and significantly increased, compared with controls. In patients with abnormally increased permeability, no increase in hydrogen breath test result was noted. From our results it can be concluded that increased intestinal permeability is present in AML patients before commencing chemotherapy. Factors other than chemotherapy would seem to be more important regarding the occurrence of intestinal disturbances in these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820631     DOI: 10.1111/j.1600-0609.1998.tb01710.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  13 in total

Review 1.  Small bowel review: normal physiology part 2.

Authors:  A B Thomson; M Keelan; A Thiesen; M T Clandinin; M Ropeleski; G E Wild
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

2.  Confirmation and prevention of intestinal barrier dysfunction and bacterial translocation caused by methotrexate.

Authors:  Desheng Song; Bin Shi; Hua Xue; Yousheng Li; Xiaodong Yang; Baojun Yu; Zhe Xu; Fukun Liu; Jieshou Li
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

3.  Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.

Authors:  H Syrjälä; P Ohtonen; U Kinnunen; R Räty; E Elonen; T Nousiainen; E Jantunen; K Remes; M Itälä-Remes; R Silvennoinen; P Koistinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-17       Impact factor: 3.267

Review 4.  The interplay between anticancer challenges and the microbial communities from the gut.

Authors:  Olivier Tenaillon; André Birgy; Claire Amaris Hobson; Stéphane Bonacorsi; André Baruchel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-03-30       Impact factor: 5.103

5.  Measuring mucosal damage induced by cytotoxic therapy.

Authors:  N M A Blijlevens; B van't Land; J P Donnelly; L M'Rabet; B E de Pauw
Journal:  Support Care Cancer       Date:  2004-01-30       Impact factor: 3.603

6.  Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis.

Authors:  B A Carneiro-Filho; I P F Lima; D H Araujo; M C Cavalcante; G H P Carvalho; G A C Brito; V Lima; S M N Monteiro; F N Santos; R A Ribeiro; A A M Lima
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

7.  'Leaky gut' in hematological malignancies.

Authors:  Carolina Costa-Lima; Erich Vinicius De Paula
Journal:  Rev Bras Hematol Hemoter       Date:  2014-10-01

8.  Intestinal permeability in leukemic patients prior to chemotherapy.

Authors:  Juliana Brovini Leite; Eduardo Garcia Vilela; Henrique Oswaldo da Gama Torres; Maria de Lourdes de Abreu Ferrari; Aloísio Sales da Cunha
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-17

9.  Bacterial translocation in acute lymphocytic leukemia.

Authors:  Yajing Song; Peter Gyarmati
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

10.  Increased gut permeability in cancer cachexia: mechanisms and clinical relevance.

Authors:  Laure B Bindels; Audrey M Neyrinck; Audrey Loumaye; Emilie Catry; Hannah Walgrave; Claire Cherbuy; Sophie Leclercq; Matthias Van Hul; Hubert Plovier; Barbara Pachikian; Luis G Bermúdez-Humarán; Philippe Langella; Patrice D Cani; Jean-Paul Thissen; Nathalie M Delzenne
Journal:  Oncotarget       Date:  2018-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.